

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

PRESS RELEASE

Stockholm June 1, 2011



Sobi's rights issue fully subscribed

Swedish Orphan Biovitrum's (Sobi) rights issue with preferential rights for the company's shareholders has been fully subscribed and the underwriting commitments do not need to be utilized. The subscription period of the rights issue ended on May 26, 2011. Approximately 99.9 per cent of the offered shares have been subscribed for with subscription rights and an additional 0.1 per cent have been subscribed for without subscription rights. In total, applications for non-preferential subscription have been received corresponding to approximately 81% of the total number of new shares. The subscription price was SEK 12 per new share and Sobi's shareholders were entitled to subscribe for one new share for each four existing shares held.

The shares that were subscribed for without subscription rights have been allocated according to the principles outlined in the prospectus that was published on May 5, 2011. Notification regarding allocation of shares that have been subscribed for without subscription rights will be distributed to those who have been allocated shares around June 1, 2011.

The rights issue provides Sobi with proceeds of approximately SEK 637 million before transaction costs. Pursuant to the rights issue Sobi's share capital will increase by SEK 29,105,800 to approximately SEK 146,664,000. The number of shares will increase by 53,045,319 common shares to a total of 267,295,132 shares¹.

The rights issue is expected to be registered with the Swedish Companies Registration Office around June 8, 2011 and trading in the new shares on NASDAQ OMX Stockholm is expected to start on June 10, 2011.

For additional information, please contact

Åsa Stenqvist, VP Communications and Investor Relations

Telephone: +46 8-697 20 00

About Swedish Orphan Biovitrum (Sobi)

Sobi is a leading European specialty pharmaceutical company. The company is focused on providing and developing specialty pharmaceuticals for patients with rare diseases and significant medical needs. The portfolio comprises about 60 marketed products, as well as projects in late clinical phase. Key therapeutic areas are hematological diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 B and approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com.

¹ Whereof 2,068,534 share of class C that are held by the company.

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on June 1, 2011 at 8.30 CET.

IMPORTANT INFORMATION

The information in this press release is not intended for distribution, publication or public release, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, Singapore, South Africa, Switzerland, the United States or any other jurisdiction where the distribution of this press release may be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction.

The information in this press release is not an offer to sell or a solicitation to buy shares. This press release is not a prospectus under the Prospectus Directive 2003/71/EC. A prospectus has been prepared and published in accordance with the Prospectus Directive. The Prospectus has also been made available by the Company. Investors shall not subscribe for securities referred to in this press release other than on the basis of the information which is included in such prospectus.

The information in this press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "Securities Act") or under the securities laws of any state or other jurisdiction in the United States, and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction in the United States. There will be no public offer of securities in the United States.

The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part may be prohibited. Failure to comply with these instructions may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

This press release may contain forward-looking statements. Words such as "expect", "believe", "estimate", "plan" and "forecast" in this press release are intended to indicate forward-looking statements. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to risks and uncertainties. All these forward-looking statements are based on the expectations and assumptions of the management and are deemed reasonable but uncertain and difficult to predict. Actual outcomes and results may differ significantly from the forward looking statements. The Company does not intend, nor undertakes, to update any such forward looking statements.